Leukemia is a cancer of the blood forming tissues, mainly the bone marrow, causing abnormal white blood cells to crowd out healthy ones. With modern treatment, many types of leukemia can be effectively controlled or even cured.
Globally, over 450,000 new cases of leukemia are diagnosed each year. Many patients are diagnosed at an advanced stage due to vague early symptoms. However, timely intervention can still open a window for curative outcomes — so prompt medical evaluation is crucial.
China sees approximately 75,000 new cases of leukemia annually, with the world's largest patient population. At Fosun Health, this extraordinary case volume has given our expert teams a depth of experience that ensures precision in every aspect of care — from accurate molecular typing and targeted therapy to immunotherapy and stem cell transplantation.
Every leukemia program has chemotherapy and transplant. Here is what makes ours different:
"They told me I have acute leukemia and may only have months without treatment. Is this the end?"
The challenge: The word "leukemia" still carries the terror of inevitable rapid death. Many patients—and even some physicians—default to despair. Yet modern leukemia care is no longer a one-size-fits-all chemotherapy blitz. Acute Promyelocytic Leukemia (APL, M3) was once the most lethal AML subtype; today, with the right protocol, it is the most curable.
Our answer: Molecular-risk-adapted therapy that treats your specific leukemia subtype, not a generic label:
- For APL (M3): ATRA (all-trans retinoic acid) + ATO (arsenic trioxide) is the China-original, globally endorsed curative protocol. Developed and pioneered in China, this non-chemotherapy combination achieves complete remission in >90% and cure in >80% of patients—without the brutal toxicity of conventional chemotherapy. This is not palliation; it is a genuine cure.
- For Philadelphia-Positive ALL or CML: Tyrosine kinase inhibitors (TKIs)—imatinib, dasatinib, ponatinib—target the BCR-ABL fusion protein with precision. Combined with low-intensity chemotherapy or as standalone chronic therapy, these transform CML into a manageable chronic disease and dramatically improve ALL outcomes.
- For FLT3-Mutated AML: Midostaurin or gilteritinib—FLT3 inhibitors added to chemotherapy or as salvage—target the mutated receptor that drives aggressive relapse.
- For IDH1/2-Mutated AML: Ivosidenib or enasidenib—oral targeted agents that induce differentiation of malignant blasts without cytotoxic chemotherapy.
- For TP53-Mutated or High-Risk AML: Venetoclax + hypomethylating agents (HMA) provides effective, lower-intensity therapy for elderly or unfit patients who cannot tolerate traditional induction.
What this means for you: "Acute leukemia" is not a single disease. Your molecular profile—whether APL, FLT3, IDH, or BCR-ABL—determines a therapy that may be curative without conventional chemotherapy, or that transforms your disease into a chronic condition you can live with.
"I have heard that during chemotherapy, my white blood cells drop to zero. A simple infection could kill me. How do you keep me alive through this?"
The challenge: Chemotherapy for leukemia destroys malignant blasts—but also annihilates normal bone marrow. Patients enter prolonged agranulocytosis (ANC = 0), where bacteria, fungi, and viruses that healthy people shrug off become lethal invaders. Mouth and gut mucosa breaks down. Platelets plummet, causing spontaneous cerebral or gastrointestinal hemorrhage. This is the phase where most leukemia deaths occur—not from the cancer itself, but from its treatment.
Our answer: A "protective bubble" system that keeps you alive when your own immune system has been erased:
- Laminar Airflow Isolation: HEPA-filtered, positive-pressure rooms with strict visitor and dietary protocols—reducing airborne pathogen exposure during the most vulnerable weeks.
- Prophylactic Anti-Infective Shield: Broad-spectrum antibiotics, antifungals (voriconazole, posaconazole), and antivirals (acyclovir) are deployed preemptively—not waiting for fever. We monitor galactomannan, β-D-glucan, and CMV/EBV viral loads with high-frequency testing to catch infections before they spiral.
- Blood Component Support: Single-donor platelet apheresis, irradiated red cell transfusions, and granulocyte colony-stimulating factor (G-CSF) are administered with precision timing—to prevent bleeding and accelerate neutrophil recovery.
- Mucositis & Nutritional Defense: Our clinical nutrition and TCM teams deploy immunonutrition (glutamine, omega-3 fatty acids) and herbal mouth rinses to protect the gastrointestinal mucosal barrier—your first line of defense against gut bacterial translocation.
- Integrative TCM: "Toxicity Reduction + Immune Rebuild"： Evidence-informed formulations help alleviate chemotherapy-induced nausea, reduce treatment-related fatigue, support platelet and white blood cell recovery, and mitigate oral mucositis. The goal is not to replace chemotherapy—it is to keep you strong enough to receive every planned dose on schedule.
What this means for you: Chemotherapy will suppress your marrow. But you will not face that abyss alone. Our protective infrastructure—air, drugs, blood, nutrition, and integrative support—is designed to carry you through the nadir and out the other side.
"I had a bone marrow transplant, but the leukemia came back. Or my donor cells are attacking my body. Is this the final chapter?"
The challenge: Allogeneic stem cell transplantation is the most powerful anti-leukemia weapon—but it is not always the last. Relapse after transplant, or severe graft-versus-host disease (GVHD), can feel like a catastrophic failure. Many patients are told "nothing more can be done" and referred for comfort care.
Our answer: A post-transplant salvage platform that fights back when the first line falters:
- CAR-T Cell Therapy: For B-cell ALL or lymphomas relapsing after transplant, CD19-directed or CD22-directed CAR-T cells are engineered from your own or donor T-cells to hunt and destroy residual leukemia blasts. Response rates in relapsed post-transplant disease can exceed 70%.
- Donor Lymphocyte Infusion (DLI): For post-transplant relapse in CML, AML, or ALL, a controlled infusion of donor immune cells triggers graft-versus-leukemia effect—the donor's immune system attacking the residual cancer—without the full intensity of a second transplant.
- Targeted Salvage: For molecular-relapse or post-transplant recurrence with identifiable mutations (FLT3, IDH, BCR-ABL), targeted agents (gilteritinib, ivosidenib, ponatinib) can re-induce remission without additional chemotherapy.
- Second Transplant: For selected patients with sustained remission after salvage therapy, a second allogeneic transplant from an alternative donor offers a genuine chance of long-term cure.
- GVHD Precision Management: For severe acute or chronic GVHD, extracorporeal photopheresis (ECP), ruxolitinib (JAK inhibitor), and mesenchymal stem cell therapy provide targeted immune modulation—controlling donor-cell aggression without sacrificing the anti-leukemia benefit.
What this means for you: A relapse after transplant is a setback, not a conclusion. We have cellular weapons, targeted drugs, and immune-modulating tools to pull you back into remission—and potentially to a second chance at cure.
"I have relapsed after chemotherapy and transplant. The drugs I need are either unavailable or cost a fortune. Is there anything left for me?"
The challenge: Relapsed or refractory leukemia—especially with adverse genetics like TP53 mutation or complex karyotype—is notoriously difficult to treat. Novel agents (menin inhibitors, BCL-2 inhibitors, novel TKIs) are transformative but often inaccessible or unaffordable outside major research centers.
Our answer: In China, the next line comes sooner—and costs significantly less:
- BCL-2 Inhibition: Venetoclax combined with azacitidine or decitabine is approved and widely used for elderly/unfit AML and has shown activity in relapsed disease.
- Menin Inhibitors: For NPM1-mutated or KMT2A-rearranged relapsed AML, this novel class disrupts the leukemogenic transcription complex—offering genuine hope where almost none existed before.
- Novel TKIs: Asciminib (STAMP inhibitor) for CML resistant to multiple prior TKIs; gilteritinib for FLT3-mutated relapsed AML.
- China-Original Arsenic & Herbal Protocols: Beyond ATO for APL, oral arsenic formulations and standardized TCM combinations that have undergone clinical trials for myelodysplastic syndrome and low-risk AML are available here—offering low-toxicity options for maintenance or palliative disease control.
- Phase III Clinical Trial Fast-Track: When approved drugs fail, rapid access to trials of bispecific T-cell engagers (BiTEs), next-generation CAR-T constructs, and novel epigenetic agents—typically 3–5 years ahead of availability elsewhere.
Because these therapies are developed and manufactured within China's integrated ecosystem, comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US—with zero compromise in quality.
Guided by NGS-based molecular profiling and physicians who have sequenced thousands of leukemia cases through multiple lines of resistance.
What this means for you: Your TP53, NPM1, or FLT3 mutation status is not a tombstone—it is a map to drugs that are available here, now, at a cost that makes sustained, multi-line treatment possible.
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs alongside your primary treatment as a "blood and marrow regenerative support system":
Toxicity Reduction: Herbal formulations help protect gastrointestinal mucosa, alleviate chemotherapy-induced nausea and vomiting, reduce treatment-related fatigue, support platelet and neutrophil recovery, and mitigate oral mucositis.
Efficacy Enhancement: Certain standardized preparations, used in conjunction with chemotherapy or targeted agents, may improve treatment tolerance and support immune reconstitution.
The goal: protect your marrow reserve, reduce infection risk, and keep you strong enough to complete every planned cycle—and emerge from transplant with robust engraftment.
Every leukemia case is reviewed by a panel comprising hematology/oncology, immunotherapy/cellular therapy specialists, infectious disease, clinical nutrition, pathology/flow cytometry, radiology, and integrative medicine experts. Leukemia decisions are uniquely complex: induction intensity selection; transplant timing and donor matching; CAR-T versus DLI versus targeted salvage for relapse; GVHD prophylaxis and management; and infection control during prolonged neutropenia.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your leukemia subtype, molecular risk profile, age, comorbidities, and your family's priorities.
Diagnosis:
FLT3-Mutated Acute Myeloid Leukemia
Treatment Plan:
Comprehensive supportive care including HEPA-filtered positive-pressure isolation, hydration therapy, tumor lysis syndrome prophylaxis, broad-spectrum antibiotics, red blood cell transfusion, and platelet support, followed by induction chemotherapy combined with targeted therapy.
Because measurable residual disease (MRD) remained persistently low-level positive after induction treatment, a next-generation BCL-2 inhibitor available in China was incorporated as bridging intensification therapy to achieve deeper remission and reduce residual disease burden prior to hematopoietic stem cell transplantation.
Outcome:
By Day 28 following treatment initiation, bone marrow blasts were reduced to less than 5%, achieving morphological remission. MRD converted to negative status, allowing successful progression to allogeneic hematopoietic stem cell transplantation.
During treatment, the patient developed mild skin rash and transient liver function abnormalities, both of which were successfully controlled with corticosteroid therapy.
At the 18-month follow-up, bone marrow evaluation demonstrated complete molecular remission, and the FLT3 mutation was no longer detectable, suggesting the possibility of long-term disease control.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your complete blood count (CBC), bone marrow aspiration and biopsy report, flow cytometry data, cytogenetics/FISH, and NGS/PCR molecular results (FLT3, NPM1, IDH, BCR-ABL, etc.). Our multidisciplinary leukemia team (hematologists, transplant physicians, immunotherapists) will provide a personalized treatment plan—including risk stratification, targeted therapy options, CAR-T candidacy, and transplant evaluation—within 48 hours.
